Article

Anti-leukemia effects of Omipalisib in Acute Myeloid Leukemia: inhibition of PI3K-AKT-mTOR signaling and suppression of Mitochondrial Biogenesis

2023-05-04

Abstract excerpt

<title>Abstract</title> <p>Omipalisib (GSK2126458), a potent dual PI3K/mTOR inhibitor, is reported to exhibit anti-tumor effect in several kinds of cancers. More than 50% of acute myeloid leukemia (AML) patients display a hyperactivation of PI3K/AKT/mTOR signaling. We investigated the anti-proliferative effect of omipalisib in AML cell lines with varied genetic backgrounds. The OCI-AML3 and THP-1 cell lines had a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 162da127-a980-52c6-9907-15457b1223c8
DOI: 10.21203/rs.3.rs-2854129/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Anti-leukemia effects of Omipalisib in Acute Myeloid Leukemia: inhibition of PI3K-AKT-mTOR signaling and suppression of Mitochondrial BiogenesisDOI 10.21203/rs.3.rs-2854129/v1Read

P422: OMIPALISIB, A DUAL PI3K/MTOR INHIBITOR, TARGETS MITOCHONDRIA AND IMPAIRS OXIDATIVE PHOSPHORYLATION IN ACUTE MYELOID LEUKEMIASemantic proximity Read

Outlook on PI3K/AKT/mTOR inhibition in acute leukemiaSemantic proximity Read

Network pharmacology-based investigation and experimental validation of the mechanism of Metformin in the treatment of acute myeloid leukemiaSemantic proximity Read

Quizartinib and omacetaxine mepesuccinate combination therapy in FLT3-ITD AML: a phase II trial.Semantic proximity Read

Targeting the mTOR Pathway in LeukemiaSemantic proximity Read

Inhibition of CPT1a as a Prognostic Marker can Synergistically Enhance the Antileukemic Activity of ABT199Semantic proximity Read

Antileukaemic effect of <scp>PI</scp>3<scp>K</scp>‐m<scp>TOR</scp> inhibitors in acute myeloid leukaemia‐gene expression profiles reveal <scp>CDC</scp>25<scp>B</scp> expression as determinate of pharmacological effectSemantic proximity Read

Anisomycin is active in preclinical models of pediatric acute myeloid leukemia via specifically inhibiting mitochondrial respiration.Semantic proximity Read

Targeting mTOR in Acute Lymphoblastic LeukemiaSemantic proximity Read

Targeting mTOR as a Cancer Therapy: Recent Advances in Natural Bioactive Compounds and ImmunotherapySemantic proximity Read

Therapeutic resistance in acute myeloid leukemia cells is mediated by a novel ATM/mTOR pathway regulating oxidative phosphorylation.Semantic proximity Read

The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagySemantic proximity Read